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Objective: Human papillomavirus (HPV) is the major cause of cervical carcinoma and cervical intraepithelial neo-
plasia worldwide. Certain HPV types have a strong association with and probably a causative role in the
pathogenesis of premalignant cervical lesions. Epidemiologic studies in women infected by the human immuno-
deficiencyvirus(HIV)haveshownanincreasedincidenceofsquamousintraepitheliallesions(SILs),whichwerepre-
dominantly high-grade. Six to 30 per cent of women diagnosed with atypical squamous cells of undetermined
significance (ASCUS) on a Papanicolaou (Pap) smear harbor SIL in normal screening populations. This study was
undertakentodeterminethe presenceof low- and high-risk HPV typesin women infectedbyHIV andtocorrelate
the results to those of the Pap smear.
Study design: HPV DNA typing (low- and high-risk) by Digeneä (Digene Corporation, Gathesburg, MD) hybrid
capturemethodology was performed on cervical swabs from 209 HIV-positive women. The results of HPV typing
were correlated with those of the Pap smear in a retrospective analysis.
Results: One hundred and one women (48%) tested positive for HPV subtypes by DNA typing by the hybrid
capturemethod.Ofthese,64patients(63%)hadPapsmearswhichwerereadasbeingnormal,havingbenigncellu-
lar changes, or having ASCUS (favor reactive process). Of these, 19 patients testedpositive for both high-risk and
low-risk subtypes, 32 patients tested positive only for high-risk subtypes, and 13 patients tested positive only for
low-risk subtypes.
Conclusion: HPV subtyping identifies a significant group of HIV-positive women who are at risk for developing
cervical intraepithelial neoplasia, although they may not show significant abnormalities on their Pap smears.
Key words: HUMAN PAPILLOMAVIRUS (HPV), HUMAN IMMUNODEFICIENCY VIRUS (HIV), ATYPICAL
SQUAMOUSCELLS OF UNCERTAIN SIGNIFICANCE (ASCUS), BENIGN CELLULAR CHANGES (BCC), SQUAMOUS
INTRAEPITHELIALLESION (SIL)
Human papillomaviruses (HPV) are small DNA
viruses that infect epithelial cells and induce a
variety of squamous proliferative lesions1. They
display tremendous diversity with more than
100 different subtypes described in the literature2.
It is well known that the majority of cervical
carcinomas (more than 90%) harbor human
papillomaviruses3 and a causative role has been
implicated4. The viral subtypes are classified into
low-risk and high-risk based on their ability to
induce virus-associated tumors. The high-risk
subtypes (HPV 16, 18, 31, 33, 35, 45, 51, 52 and
56) are associated with cervical intraepithelial
neoplasia that may progress to carcinoma5. In the
current Bethesda system for cytology screening
(Pap smear), the most common abnormal result is
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Clinical study 89oneofuncertainty,termed ‘atypicalsquamouscells
of uncertain significance’ (ASCUS). In the United
Statesabout2millionASCUS Papsmear resultsare
reported every year6. Of these, any proportion
between 6 and 30% can harbor squamous intra-
epithelial lesions (SILs)7.
Women infected with human immunodefi-
ciency virus (HIV) show an increased incidence of
SILs and the majority of these are high-grade SILs
as reported by epidemiologic studies8. This study
was undertaken to correlate the presence of low-
and high-risk subtype HPV with Pap smear results
in HIV-positive women.
MATERIALS AND METHODS
Approval from the institutional review board
(IRB) wasobtainedpriortoinitiationofthisstudy.
Two hundred and nine HIV-positive women
who were being monitored by HIV viral load and
for whom HPV typing had been performed by the
DigeneÔ(DigeneCorporation,Gathesburg,MD)
hybrid capture method as a routine clinical test
were selected from a database at the Molecular
Diagnostics Laboratory at the New Jersey Medical
School.The correspondingPap smear results were
obtained from the Division of Cytology at the
same institution and the results were correlated
with the findings of HPV typing. All normal,
benign cellular changes, and ASCUS results were
reconfirmed by one of us (DH).
HPV typing by Digene hybrid capture
The Digene hybrid capture HPV DNA assay is a
hybridization antibody capture assay using chemi-
luminescence to qualitatively detect the presence
of 14 HPV subtypes (6, 11, 16, 18, 31, 33, 35, 42,
43, 44, 45, 51, 52 and 56). The assay is designed
to distinguish between two HPV DNA
groups, low-risk (6, 11, 42, 43 and 44) and high-
intermediaterisk (16,18, 31,33, 35, 45,51, 52and
56), in cervical specimens (cervical swabs and fresh
cervical biopsies). Briefly, specimens containing
the target DNA hybridize with a specific HPV
RNA probe cocktail. The resultant RNA:DNA
hybrids are captured onto the surface of a tube
coated with antibodies specific for RNA:DNA
hybrids. Immobilized hybrids are then reacted
with alkaline phosphatase-conjugated antibodies
specific for the RNA:DNA hybrids, and then
detectedwithachemiluminescentsubstrate.Asthe
substrate is cleaved by the bound alkaline
phosphatase, light is emitted which is measured as
relative light units (RLUs) on a luminometer. The
intensity of the light emitted denotes the presence
or absence of target DNA in the specimen. Com-
putations were performed using StatXact® soft-
ware (Cytel, Cambridge, MA). Ninety-five per
cent confidence intervals based on the binomial
distribution were computed for estimates of pro-
portions with positive and negative results.
RESULTS
One hundred and one patients (48%) tested posi-
tive for HPV (either low- or high-risk) subtypes.
Of these, the Pap smear results were read as
normal, or revealed benign cellular changes or
ASCUS (favor reactive process), in 64 patients
(63%). Of the 64 patients, 19 (30%) were positive
for both high-risk and low-risk subtypes, an addi-
tional 32 (50%) tested positive for high-risk HPV
subtypes, and the remaining 13 patients (20%)
tested positive for low-risk subtypes.
Twenty-four of the 209 patients (11%) had
low-grade SIL on Pap smear. Among the low-
grade SIL patients, 12 tested positive for high-risk
subtypes only, two for low-risk subtypes only, and
nine for both subtypes. One patient with low-
grade SIL tested negative for HPV subtyping.
Twelve patients(0.06%) had Pap smears diagnosed
as ASCUS (favor dysplasia). Of these, seven
showed positivity for both subtypes, (one for
high-risk only) and four tested negative for HPV
subtyping.Only three patients showed high-grade
SIL, of which two were positive for both subtypes
and one for low-risk subtypes only. Of three
patients diagnosed on Pap smear with dysplasia
(grade cannot be determined), two had only high-
risk subtypes and one tested positive for low-risk
subtypesonly.Resultsaresummarized inTable1.
Ofthe101HPV-positivepatients,64(63%)had
a Pap smear showing ASCUS (favor reactive
process), benign cellular changes, or a normal
result. Of these, 45 (45%) had benign cellular
changesor normalfindings(95% confidenceinter-
val (CI) 35–55%) and 19 were read as ASCUS
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(reactive) and/or normal/ benign cellular changes
patients, 51 (80%) had high-risk HPV subtypes
(95% CI 68–89%).Only 37 HPV-positive patients
had abnormal Pap smears, denoting a sensitivity of
only 37% (95% CI 27–47%)for Pap smear alone to
detect the HPV-positive individuals.
DISCUSSION
In the past 40 years there has been a dramatic
decline in the incidence of cervical carcinoma in
the United States due to the widespread use of
cytologic screening, which can detect premalig-
nant lesions (SILs) that can be treated successfully.
However, there is considerable interlaboratory
variability in detection of SILs and up to 20% of
SILs can go undetected by routine screening
procedures9–12. Additionally 5–10% of women
with the diagnosis of ASCUS harbor SILs and
morethanone-thirdofscreening populationswho
harborhigh-gradeintraepitheliallesionsareidenti-
fiedfromASCUS results6.ThecentralroleofHPV
as a causative phenomenon in cervical intra-
epithelial neoplasia has been well established by
experimental and epidemiologica data13–15. The
recognition of certain HPV types such as 16, 18,
31, 33, 35, 45, 51, 52 and 56 as underlying
etiologic agents for cervical carcinoma has raised
the expectation that HPV DNA typing may be of
value in identifying women at risk of developing
premalignantlesionsofthecervix. HPVisdetected
byPCRanalysisincervical cancersinabout90%of
cases16,17 and the prevalence is strongly correlated
to the grade of SIL18. It has also been shown that
the presence of HPV DNA as determined by dot
blot hybridization correlated with the detection of
high-grade SIL within 3 years19.
Women infected with HIV are five times more
likely to develop cervical carcinoma than un-
infected women20. Some studies have suggested
that HIV infection increases the strength of associ-
ation between HPV and SIL and that the viral
pathogenic effect is probably mediated through
HIV-mediated immune suppression21,22. The
number of sex partners and CD4 cell count can
affect the association between HPV and HIV23,24.
It has also been shown that the incidence of false
negative findings following a single Pap smear in
the presence of histologically confirmed SIL or
invasive carcinoma could be as high as 50% in
HIV-positive women25.
In this study we found that there is high preva-
lence of HPV in HIV-positive women (47%), a
finding similar to many reports in the litera-
ture26–30. Sixty-three percent of patients who
showed normal or minimally abnormal Pap smear
results tested positive for HPV in our study. A
similar finding is reported by Uberti-Foppa and
colleagues27. In their study, 63% of cytologically
negative HIV-positive women tested positive for
HPV high-risk subtypes by the hybrid capture
method. This also supports the view that HPV
infection is more persistent in women who are at
risk for developing cervical neoplasia than in
others31. A noteworthy finding in our study is the
high prevalence of HPV among patients with
normal or benign cellular changes (45 of 101
patients). The majority of these patients also
harbored high-risk subtypes (36 of 45) which
are similar to the data of Uberti-Foppa and
colleagues27. The high percentage of HPV
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HPV subtypes Normal/BCC
ASCUS
(reactive)
ASCUS
(dysplasia) LGSIL HGSIL
Dysplasia/
?grade Total
Low-risk only
High-risk only
Both high-risk and
low-risk subtypes
Total HPV-positive
Both subtypes negative
9
25
11
45
97
4
7
8
19
6
0
1
7
8
4
2
12
9
23
1
1
0
2
3
0
0
2
1
3
0
16
47
38
101
108
ASCUS, atypical cells of undetermined significance; BCC, benign cellular changes; HGSIL, high-grade squamous intraepithelial lesion; LGSIL,
low-grade squamous intraepithelial lesion
Table 1 Correlation between human papillomavirus (HPV) test results and Pap smear findingspositivity with negative cytology in our study
reduces the sensitivity of the Pap smear to 37% for
detectingpatientsat highrisk fordevelopingcervi-
cal intraepithelial neoplasia in this population of
HIV-infected women. Of the 101 HPV-positive
patients we tested, 19 showed ASCUS (favor re-
active process) by Pap smear. Fifteen of the 19
patients harbored high-risk HPV subtypes. In a
largecohortstudybyManosandco-workers,HPV
DNA testing was recommended for women with
ASCUS Pap smear results to help identify those
who may have underlyinghigh-grade SIL6. In our
study, 80% of HPV-positive patients with normal,
benign cellular changes, or ASCUS (favor reactive
process) Pap smears tested positive for high-risk
HPV subtypes.These findings suggest that routine
screening ofcervical cytologyshouldincludeHPV
subtype identification in HIV-infected women
especially in areas where careful cytologic screen-
ingover timemay notbefeasible dueto issues such
as noncompliance in the screening population.
Ourresults indicatethata Papsmear alonemay not
exclude HPV infection. Furthermore, a significant
number of patients who are at risk of cervical
intraepithelial neoplasia can be identified by HPV
DNA subtyping in addition to thePap smear. This
approach wouldalso ensure appropriatefollow-up
and treatment of cervical SIL in a timely fashion in
HIV-positive women where rapid progression of
disease is a strong possibility.
HPV typing in HIV-positive women Hameed et al.
92 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
REFERENCES
1. Alani MR, Munger K. Human papilloma viruses
and associated malignancies. J Clin Oncol 1998;
16:330–7
2. RaymondK,Ervin A,VladimirV.Humanpapillo-
mavirus infection and cervical carcinoma. Clin
Obstet Gynecol 2000;43:363–80
3. DeVilliers EM. Heterogeneity of the human
papilloma virus group. J Virol 1989;63:4898–903
4. Farthing A, Masterson P, Mason WP, Vousden
KH. Human papilloma virus detection by hybrid
capture and its possible clinical use. J Clin Pathol
1994;47:649–52
5. Lorincz A, Temple GF, Kurman RJ, et al. Onco-
genic association of specific human papillomavirus
types with cervical neoplasia. J Natl Cancer Inst
1987;79:671–7
6. Manos MM, Kinney WK, Hurley LB, et al. Iden-
tifying women with cervical neoplasia. Using
human papillomavirus DNA testing for equivocal
Papanicolaou results. JAMA 1999;281:1605–10
7. Crum CP, Genest DR, Krane JF, et al. Sub-
classifying atypical squamous cells in thin-prep
cervical cytology correlates with detection of
high-risk human papillomavirus DNA. Am J Clin
Pathol 1999;112:384–90
8. Wright TC, Sun XW. Anogenital papillomavirus
infection and neoplasia in immunodeficient
women. Obstet Gynecol 1996;23:861–93
9. Cox JT, Lorincz AT, SchiffmanMH, et al. Human
papillomavirus testing by hybrid capture appears
to be useful in triaging women with a cyto-
logical diagnosis of atypical squamous cells of
undetermined significance. Am J Obstet Gynecol
1995; 172:946–54
10. Reid R, Greenberg MD, Lorincz A, et al. Should
cervical cytological testing be augmented by
cervicography or human papillomavirus deoxyri-
bonucleic acid detection? Am J Obstet Gynecol
1991;164:1461–71
11. Wright TC, Sun XW, Koulos J. Comparison of
management algorithms for the evaluation of
women with low grade cytologic abnormalities.
Obstet Gynecol 1995;85:202–10
12. Davey DD, Naryshkin S, Nielsen ML, Kline TS.
Atypical squamous cells of undetermined signifi-
cance; interlaboratory comparison and quality
assurance of monitors. Diagn Cytopathol 1994;
11:390–6
13. zur Hausen H, de Villiers EM, Gissman L. Papillo-
mavirus infections and human genital cancer.
Gynecol Oncol 1981;12(Suppl 1):124–8
14. International Agency Research on Cancer. The
Epidemiology of Human Papillomavirus and Cervical
Cancer. International Agency Research on Cancer
scientific monograph 119. Lyon, France: IARC,
1992
15. Schiffman MH. Recent progress in defining the
epidemiology of human papillomavirus infection
and cervical neoplasia. J Natl Cancer Inst 1992;
84:394–8
16. FujinagaY,ShimadaM,OkazawaK, etal. Simulta-
neous detection and typing of genital human
papillomavirus DNA using polymerase chain re-
action. J Gen Virol 1991;72:1039–4417. Kiyabu MT, Shibata D, Arnheim N, et al. Detec-
tion of human papillomavirus in formalin fixed
invasive squamous carcinomas using the poly-
merase chain reaction. Am J Surg Pathol 1989;13:
221–4
18. Cuzick J, Terry G, Hollingworth T, Anderson M.
Human papilloma virus type 16 in cervical smears
as predictor of high grade cervical intraepithelial
neoplasia. Lancet 1992;339:959–60
19. Koutsky LA, Holmes KK, Critchlow CW, et al. A
cohort study of the risk of cervical intraepithelial
neoplasia grade 2 or 3 in relation to papillomavirus
infection. N Engl J Med 1992;327:1272–8
20. MandelblattJS, Fahs M, Garibaldi K, et al. Associa-
tion betweenHIV infection andcervical neoplasia:
implications of clinical care of women at risk for
both conditions. AIDS 1992;6:173–8
21. Laga M, Icenogle JI, Marsella R, et al. Genital
papillomavirus infection and cervical dysplasia –
opportunistic complication of HIV infection. Int J
Cancer 1992;50:45–8
22. Schrager LK,Friedland GHD,MaudeSchreiber K,
etal.Cervical andvaginalsquamouscell abnormali-
ties in women infected with human immuno-
deficiency virus. J AIDS 1989;2:570–3
23. Piper MA, Severin ST, Wiktor AZ, et al. Associa-
tion of human papilloma virus with HIV and CD4
cell count in women with high or low numbers of
sex partners. Sex Transmiss Inf 1999;75:253–7
24. Vernon SD, Unger ER, Piper MA, et al. HIV and
human papillomavirus as independent risk factors
for cervical neoplasia in women with high or low
numbers of sex partners. Sex Transmiss Inf 1999;
75:258–60
25. Syrjanen S, Saastamoinen J, Chang F, et al.
Colposcopy,punchbiopsy,insituDNAhybridiza-
tionandthepolymerasechain reaction insearching
for genitalhuman papillomavirus (HPV) infections
in women with normal Pap smears. J Med Virol
1990;31:259–66
26. Rezza G, Giuliani M, Branca M, et al., and the
DIANAIDS CollaborativeStudyGroup.Determi-
nants of squamous intraepithelial lesions (SIL) on
Papsmear:therole ofHPV infectionandofHIV-1
inducedimmunosuppression.EurJEpidemiol 1997;
13:937–43
27. Uberti-Foppa C, Origoni M, Maillard M, et al.
Evaluation of the detection of human papilloma-
virus genotypes in cervical specimens by hybrid
capture as screening for precancerous lesions in
HIV positive women. J Med Virol 1998;56:133–7
28. Ho GYF, Burk RD, Fleming I, Klein RS. Risk of
genital human papillomavirus infection in women
with human immunodeficiency virus induced
immunosuppression.Int J Cancer 1994;56:788–92
29. Tweddel G, Heller P, Cunnane M, et al. The
correlation between HIV seropositivity, cervical
dysplasia and HPV sub types 6/11, 16/18,
31/33/35. Gynecol Oncol 1994; 52:161–4
30. Vernon SD, Holmes KK, Reeves WC. Human
papillomavirus infection and associated disease in
persons infected with human immunodeficiency
virus. Clin Infect Dis 1995;21:121–4
31. Hildesheim A, Schiffman MH, Gravitt PE, et al.
Persistence of type specific human papillomavirus
infection among cytologically normal women.
J Infect Dis 1994;169:235–40
RECEIVED 09/05/00; ACCEPTED 01/19/01
HPV typing in HIV-positive women Hameed et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 93